Correction: Effectiveness of plasma lyso-Gb3 as a biomarker for selecting high-risk patients with Fabry disease from multispecialty clinics for genetic analysis (Genetics in Medicine, (2019), 21, 1, (44-52), 10.1038/gim.2018.31)

Hiroki Maruyama; Kaori Miyata; Mariko Mikame; Atsumi Taguchi; Chu Guili; Masaru Shimura; Kei Murayama; Takeshi Inoue; Saori Yamamoto; Koichiro Sugimura; Koichi Tamita; Toshihiro Kawasaki; Jun Kajihara; Akifumi Onishi; Hitoshi Sugiyama; Teiko Sakai; Ichijiro Murata; Takamasa Oda; Shigeru Toyoda; Kenichiro Hanawa; Takeo Fujimura; Shigehisa Ura; Mimiko Matsumura; Hideki Takano; Satoshi Yamashita; Gaku Matsukura; Ryushi Tazawa; Tsuyoshi Shiga; Mio Ebato; Hiroshi Satoh; Satoshi Ishii

doi:10.1038/s41436-018-0125-2

Correction: Effectiveness of plasma lyso-Gb3 as a biomarker for selecting high-risk patients with Fabry disease from multispecialty clinics for genetic analysis (Genetics in Medicine, (2019), 21, 1, (44-52), 10.1038/gim.2018.31)

Hiroki Maruyama, Kaori Miyata, Mariko Mikame, Atsumi Taguchi, Chu Guili, Masaru Shimura, Kei Murayama, Takeshi Inoue, Saori Yamamoto, Koichiro Sugimura, Koichi Tamita, Toshihiro Kawasaki, Jun Kajihara, Akifumi Onishi, Hitoshi Sugiyama, Teiko Sakai, Ichijiro Murata, Takamasa Oda, Shigeru Toyoda, Kenichiro HanawaTakeo Fujimura, Shigehisa Ura, Mimiko Matsumura, Hideki Takano, Satoshi Yamashita, Gaku Matsukura, Ryushi Tazawa, Tsuyoshi Shiga, Mio Ebato, Hiroshi Satoh, Satoshi Ishii

Research output: Contribution to journal › Comment/debate › peer-review

1 Citation (Scopus)

Abstract

In the above article, we noticed that one female patient in the positive group (plasma lyso-Gb3 7.6 ng/ml, α-galactosidase A activity 4.9 nmol/h/ml) who presented at the neurology clinic was already diagnosed with Fabry disease before the current study. We excluded patients with a confirmed diagnosis of Fabry disease and those with relatives known to have Fabry disease. To accurately describe the information in the current study, we must exclude this patient from the analysis. We have accurately revised this information as follows:

Original language	English
Pages (from-to)	512-515
Number of pages	4
Journal	Genetics in Medicine
Volume	21
Issue number	2
DOIs	https://doi.org/10.1038/s41436-018-0125-2 https://doi.org/10.1038/s41436-018-0125-2
Publication status	Published - Feb 1 2019

ASJC Scopus subject areas

Genetics(clinical)

Access to Document

Fingerprint

Dive into the research topics of 'Correction: Effectiveness of plasma lyso-Gb3 as a biomarker for selecting high-risk patients with Fabry disease from multispecialty clinics for genetic analysis (Genetics in Medicine, (2019), 21, 1, (44-52), 10.1038/gim.2018.31)'. Together they form a unique fingerprint.

Cite this

Maruyama, H., Miyata, K., Mikame, M., Taguchi, A., Guili, C., Shimura, M., Murayama, K., Inoue, T., Yamamoto, S., Sugimura, K., Tamita, K., Kawasaki, T., Kajihara, J., Onishi, A., Sugiyama, H., Sakai, T., Murata, I., Oda, T., Toyoda, S., ... Ishii, S. (2019). Correction: Effectiveness of plasma lyso-Gb3 as a biomarker for selecting high-risk patients with Fabry disease from multispecialty clinics for genetic analysis (Genetics in Medicine, (2019), 21, 1, (44-52), 10.1038/gim.2018.31). Genetics in Medicine, 21(2), 512-515. https://doi.org/10.1038/s41436-018-0125-2, https://doi.org/10.1038/s41436-018-0125-2

Correction : Effectiveness of plasma lyso-Gb3 as a biomarker for selecting high-risk patients with Fabry disease from multispecialty clinics for genetic analysis (Genetics in Medicine, (2019), 21, 1, (44-52), 10.1038/gim.2018.31). / Maruyama, Hiroki; Miyata, Kaori; Mikame, Mariko et al.

In: Genetics in Medicine, Vol. 21, No. 2, 01.02.2019, p. 512-515.

Research output: Contribution to journal › Comment/debate › peer-review

Maruyama, H, Miyata, K, Mikame, M, Taguchi, A, Guili, C, Shimura, M, Murayama, K, Inoue, T, Yamamoto, S, Sugimura, K, Tamita, K, Kawasaki, T, Kajihara, J, Onishi, A, Sugiyama, H, Sakai, T, Murata, I, Oda, T, Toyoda, S, Hanawa, K, Fujimura, T, Ura, S, Matsumura, M, Takano, H, Yamashita, S, Matsukura, G, Tazawa, R, Shiga, T, Ebato, M, Satoh, H & Ishii, S 2019, 'Correction: Effectiveness of plasma lyso-Gb3 as a biomarker for selecting high-risk patients with Fabry disease from multispecialty clinics for genetic analysis (Genetics in Medicine, (2019), 21, 1, (44-52), 10.1038/gim.2018.31)', Genetics in Medicine, vol. 21, no. 2, pp. 512-515. https://doi.org/10.1038/s41436-018-0125-2, https://doi.org/10.1038/s41436-018-0125-2

Maruyama H, Miyata K, Mikame M, Taguchi A, Guili C, Shimura M et al. Correction: Effectiveness of plasma lyso-Gb3 as a biomarker for selecting high-risk patients with Fabry disease from multispecialty clinics for genetic analysis (Genetics in Medicine, (2019), 21, 1, (44-52), 10.1038/gim.2018.31). Genetics in Medicine. 2019 Feb 1;21(2):512-515. https://doi.org/10.1038/s41436-018-0125-2, https://doi.org/10.1038/s41436-018-0125-2

@article{d8629bcc5f2f4cadae06f8237c3e6fd9,

title = "Correction: Effectiveness of plasma lyso-Gb3 as a biomarker for selecting high-risk patients with Fabry disease from multispecialty clinics for genetic analysis (Genetics in Medicine, (2019), 21, 1, (44-52), 10.1038/gim.2018.31)",

abstract = "In the above article, we noticed that one female patient in the positive group (plasma lyso-Gb3 7.6 ng/ml, α-galactosidase A activity 4.9 nmol/h/ml) who presented at the neurology clinic was already diagnosed with Fabry disease before the current study. We excluded patients with a confirmed diagnosis of Fabry disease and those with relatives known to have Fabry disease. To accurately describe the information in the current study, we must exclude this patient from the analysis. We have accurately revised this information as follows:",

author = "Hiroki Maruyama and Kaori Miyata and Mariko Mikame and Atsumi Taguchi and Chu Guili and Masaru Shimura and Kei Murayama and Takeshi Inoue and Saori Yamamoto and Koichiro Sugimura and Koichi Tamita and Toshihiro Kawasaki and Jun Kajihara and Akifumi Onishi and Hitoshi Sugiyama and Teiko Sakai and Ichijiro Murata and Takamasa Oda and Shigeru Toyoda and Kenichiro Hanawa and Takeo Fujimura and Shigehisa Ura and Mimiko Matsumura and Hideki Takano and Satoshi Yamashita and Gaku Matsukura and Ryushi Tazawa and Tsuyoshi Shiga and Mio Ebato and Hiroshi Satoh and Satoshi Ishii",

year = "2019",

month = feb,

day = "1",

doi = "10.1038/s41436-018-0125-2",

language = "English",

volume = "21",

pages = "512--515",

journal = "Genetics in Medicine",

issn = "1098-3600",

publisher = "Lippincott Williams and Wilkins",

number = "2",

}

TY - JOUR

T1 - Correction

T2 - Effectiveness of plasma lyso-Gb3 as a biomarker for selecting high-risk patients with Fabry disease from multispecialty clinics for genetic analysis (Genetics in Medicine, (2019), 21, 1, (44-52), 10.1038/gim.2018.31)

AU - Maruyama, Hiroki

AU - Miyata, Kaori

AU - Mikame, Mariko

AU - Taguchi, Atsumi

AU - Guili, Chu

AU - Shimura, Masaru

AU - Murayama, Kei

AU - Inoue, Takeshi

AU - Yamamoto, Saori

AU - Sugimura, Koichiro

AU - Tamita, Koichi

AU - Kawasaki, Toshihiro

AU - Kajihara, Jun

AU - Onishi, Akifumi

AU - Sugiyama, Hitoshi

AU - Sakai, Teiko

AU - Murata, Ichijiro

AU - Oda, Takamasa

AU - Toyoda, Shigeru

AU - Hanawa, Kenichiro

AU - Fujimura, Takeo

AU - Ura, Shigehisa

AU - Matsumura, Mimiko

AU - Takano, Hideki

AU - Yamashita, Satoshi

AU - Matsukura, Gaku

AU - Tazawa, Ryushi

AU - Shiga, Tsuyoshi

AU - Ebato, Mio

AU - Satoh, Hiroshi

AU - Ishii, Satoshi

PY - 2019/2/1

Y1 - 2019/2/1

N2 - In the above article, we noticed that one female patient in the positive group (plasma lyso-Gb3 7.6 ng/ml, α-galactosidase A activity 4.9 nmol/h/ml) who presented at the neurology clinic was already diagnosed with Fabry disease before the current study. We excluded patients with a confirmed diagnosis of Fabry disease and those with relatives known to have Fabry disease. To accurately describe the information in the current study, we must exclude this patient from the analysis. We have accurately revised this information as follows:

AB - In the above article, we noticed that one female patient in the positive group (plasma lyso-Gb3 7.6 ng/ml, α-galactosidase A activity 4.9 nmol/h/ml) who presented at the neurology clinic was already diagnosed with Fabry disease before the current study. We excluded patients with a confirmed diagnosis of Fabry disease and those with relatives known to have Fabry disease. To accurately describe the information in the current study, we must exclude this patient from the analysis. We have accurately revised this information as follows:

UR - http://www.scopus.com/inward/record.url?scp=85061209550&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061209550&partnerID=8YFLogxK

U2 - 10.1038/s41436-018-0125-2

DO - 10.1038/s41436-018-0125-2

M3 - Comment/debate

C2 - 30190610

VL - 21

SP - 512

EP - 515

JO - Genetics in Medicine

JF - Genetics in Medicine

SN - 1098-3600

IS - 2

ER -

Correction: Effectiveness of plasma lyso-Gb3 as a biomarker for selecting high-risk patients with Fabry disease from multispecialty clinics for genetic analysis (Genetics in Medicine, (2019), 21, 1, (44-52), 10.1038/gim.2018.31)

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this